Marsha E Samson1, Swann Arp Adams2, Caroline M Mulatya3, Jiajia Zhang3, Charles L Bennett4, James Hebert5, Susan E Steck5. 1. Cancer Prevention and Control Program, University of South Carolina, United States; Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, United States. Electronic address: msamson@email.sc.edu. 2. Cancer Prevention and Control Program, University of South Carolina, United States; Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, United States; College of Nursing, University of South Carolina, United States. 3. Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, United States. 4. College of Pharmacy, University of South Carolina, United States. 5. Cancer Prevention and Control Program, University of South Carolina, United States; Epidemiology & Biostatistics, Arnold School of Public Health, University of South Carolina, United States.
Abstract
INTRODUCTION: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) and breast cancer, there is a paucity of literature that discusses progestin-only oral contraceptives (POCs) and breast cancer. The purpose of this investigation is to examine potential associations between different types of oral contraceptives and breast cancer mortality in the South Carolina Medicaid population among different racial/ethnic groups. METHODS: Subjects included 4816 women diagnosed with breast cancer between 2000 and 2013. Kaplan-Meier curves were calculated to determine time-to-mortality rates among users of oral contraceptives. Competing-risks models and Cox multivariate survival models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer and other-cause mortality, as well as all-cause mortality. RESULTS: POCs were associated with a significantly decreased risk of breast cancer mortality (HR: 0.07; 95% CI: 0.01, 0.52) and a non-significant increased risk of all-cause mortality (HR: 1.04; 95% CI: 0.52, 2.07). COCs increased the risk of breast cancer mortality (HR: 1.61; 95% CI: 1.14, 2.28) and all-cause mortality (HR: 1.83; 95% CI: 1.30, 2.57). CONCLUSION: Use of POCs may be associated with a decreased risk of breast cancer mortality. Due to the small sample size of POC users in the current study, additional research is needed to confirm these findings. Copyright Â
INTRODUCTION: Oral contraceptive pills have been implicated in the pathophysiology of breast cancer. Although many studies have examined the relationship between combined oral contraceptives (COCs) and breast cancer, there is a paucity of literature that discusses progestin-only oral contraceptives (POCs) and breast cancer. The purpose of this investigation is to examine potential associations between different types of oral contraceptives and breast cancer mortality in the South Carolina Medicaid population among different racial/ethnic groups. METHODS: Subjects included 4816 women diagnosed with breast cancer between 2000 and 2013. Kaplan-Meier curves were calculated to determine time-to-mortality rates among users of oral contraceptives. Competing-risks models and Cox multivariate survival models were used to estimate the hazard ratios (HRs) and 95% confidence intervals (CIs) of breast cancer and other-cause mortality, as well as all-cause mortality. RESULTS: POCs were associated with a significantly decreased risk of breast cancer mortality (HR: 0.07; 95% CI: 0.01, 0.52) and a non-significant increased risk of all-cause mortality (HR: 1.04; 95% CI: 0.52, 2.07). COCs increased the risk of breast cancer mortality (HR: 1.61; 95% CI: 1.14, 2.28) and all-cause mortality (HR: 1.83; 95% CI: 1.30, 2.57). CONCLUSION: Use of POCs may be associated with a decreased risk of breast cancer mortality. Due to the small sample size of POC users in the current study, additional research is needed to confirm these findings. Copyright Â
Authors: Marsha E Samson; Swann A Adams; Anwar T Merchant; Whitney D Maxwell; Jiajia Zhang; Charles L Bennett; James R Hebert Journal: Arch Gynecol Obstet Date: 2016-07-11 Impact factor: 2.344
Authors: Marsha Samson; Nancy Porter; Olubunmi Orekoya; James R Hebert; Swann Arp Adams; Charles L Bennett; Susan E Steck Journal: Breast Cancer Res Treat Date: 2015-12-23 Impact factor: 4.872
Authors: Björn Logi Isfoss; Bo Holmqvist; Elin Sand; Johan Forsell; Helena Jernström; Håkan Olsson Journal: BMC Cancer Date: 2018-02-27 Impact factor: 4.430